Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study
- 1 February 2001
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 37 (3) , 364-368
- https://doi.org/10.1016/s0959-8049(00)00400-7
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- bcl-2 inhibits mitochondrial metabolism and lonidamine-induced apoptosis in adriamycin-resistant mcf7 cellsInternational Journal of Cancer, 1999
- Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition poreOncogene, 1999
- Lonidamine as a modulator of taxol activity in human ovarian cancer cells: effects on cell cycle and induction of apoptosisInternational Journal of Cancer, 1998
- Stimulation of the apoptotic response as a basis for the therapeutic synergism of lonidamine and cisplatin in combination in human tumour xenografts.British Journal of Cancer, 1998
- Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum.Journal of Clinical Oncology, 1997
- New Therapy for Ovarian CancerNew England Journal of Medicine, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Enhancement of cisplatin activity by lonidamine in human ovarian cancer cellsInternational Journal of Cancer, 1992
- Reporting results of cancer treatmentCancer, 1981
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958